Other authors also demonstrated the importance of inhibiting MAPK-ERK and PI3K-AKT pathways due to their ability to reduce NRF2 levels and prevent therapy resistance in ALL [43]. The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.